The Defense Health Agency awarded Hologic Sales and Service, LLC a firm fixed-price purchase order valued at $5.9 million for laboratory molecular assay analyzers on July 1, 2025. The contract, which extends through June 30, 2030, fulfills a competitive solicitation for a high-volume molecular microbiology nucleic acid amplification testing system at Naval Medical Center Portsmouth in Virginia. The procurement includes two analyzer systems and one aliquoting sample processing system, along with comprehensive software licenses, services, and maintenance support. The solution is designed to interface with the MHS Genesis electronic health record system and will focus on Women's Health testing assays, including Chlamydia/Gonorrhea, Trichomonas, and HPV testing capabilities. Hologic Sales and Service, LLC will provide approximately 21-34 different molecular testing products under a cost-per-test model with reagents and maintenance services included.
This award reflects the Defense Health Agency's continued investment in advanced diagnostic capabilities across the Military Health System and demonstrates Hologic's established position as a key provider of medical technology solutions to federal healthcare agencies. The contract was awarded without a set-aside designation under full and open competition, underscoring Hologic's competitive strength as a full-sized enterprise. As a subsidiary of Hologic, Inc., a Massachusetts-based medical technology company, the contractor brings extensive experience in diagnostic equipment and laboratory reagents, with prior indefinite delivery contracts and task orders from the Department of Veterans Affairs and other federal health entities totaling hundreds of thousands of dollars.